

G. F. Bottazzo · E. Bosi · C. A. Cull · E. Bonifacio ·
M. Locatelli · P. Zimmet · I. R. Mackay · R. R. Holman

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)

Published online: 19 May 2005
© Springer-Verlag 2005

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-005-1691-9>

G. F. Bottazzo · M. Locatelli
Scientific Directorate, Bambino Gesù Paediatric Hospital,
Scientific Institute,
Rome, Italy

E. Bosi · E. Bonifacio
General Medicine, Diabetes and Endocrinology Unit,
San Raffaele Vita-Salute University Hospital,
Milan, Italy

C. A. Cull (✉) · R. R. Holman
Diabetes Trials Unit, Oxford Centre for Diabetes,
Endocrinology and Metabolism, Churchill Hospital,
Old Road, Headington,
Oxford, OX3 7LJ, UK
e-mail: carole.cull@dtu.ox.ac.uk
Tel.: +44-1865-857251
Fax: +44-1865-857254

P. Zimmet
International Diabetes Institute,
Caulfield, Victoria, Australia

I. R. Mackay
Department of Biochemistry and Molecular Biology,
Monash University,
Clayton, Victoria, Australia

Diabetologia (2005) 48:703–708

Unfortunately there was a mistake in the sub-section of the Results entitled 'IA-2A, ICA, GADA and early requirement for insulin therapy'. The last sentence reads:

Patients older than 45 years at diagnosis were more likely to require insulin than those aged 45 years or less (23.4 vs 7.8% respectively, $p < 0.00001$).

It should read:

Patients younger than 45 years at diagnosis were more likely to require insulin than those aged 45 years or more (23.4 vs 7.8% respectively, $p < 0.00001$).